Spectrum Pharmaceuticals Inc. (SPPI)

22.48
2.00 9.90
NASDAQ : Health Technology
Prev Close 20.46
Open 20.83
Day Low/High 20.66 / 22.64
52 Wk Low/High 5.47 / 23.50
Volume 1.52M
Avg Volume 1.03M
Exchange NASDAQ
Shares Outstanding 100.66M
Market Cap 2.13B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of March 16th Options Trading For Spectrum Pharmaceuticals (SPPI)

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new March 16th contracts and identified one put and one call contract of particular interest.

SPPI December 21st Options Begin Trading

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading today, for the December 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 332 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Spectrum Pharmaceuticals To Present Corporate Update At The Noble Capital Markets' Fourteenth Annual Investor Conference

Spectrum Pharmaceuticals To Present Corporate Update At The Noble Capital Markets' Fourteenth Annual Investor Conference

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Spectrum Pharmaceuticals Announces Leadership Changes

Spectrum Pharmaceuticals Announces Leadership Changes

Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its Board of...

Spectrum Pharmaceuticals Highlights Two Oral Presentations On FOLOTYN® (pralatrexate Injection) at The 59th Annual Meeting Of The American Society Of Hematology (ASH)

Spectrum Pharmaceuticals Highlights Two Oral Presentations On FOLOTYN® (pralatrexate Injection) at The 59th Annual Meeting Of The American Society Of Hematology (ASH)

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced two oral presentations of data...

Spectrum Pharmaceuticals Highlights 15 Abstracts At The 59th Annual Meeting Of The American Society Of Hematology (ASH) In Atlanta, Georgia, December 9-12, 2017

Spectrum Pharmaceuticals Highlights 15 Abstracts At The 59th Annual Meeting Of The American Society Of Hematology (ASH) In Atlanta, Georgia, December 9-12, 2017

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of...

Spectrum Pharmaceuticals Stock Sees Short Interest Move 11.2% Higher

The most recent short interest data has been released for the 11/15/2017 settlement date, which shows a 805,681 share increase in total short interest for Spectrum Pharmaceuticals Inc , to 8,021,402, an increase of 11.17% since 10/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2017 London Healthcare Conference On November 15th

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2017 London Healthcare Conference On November 15th

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an...

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.

Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced today financial results for...

Spectrum Pharmaceuticals Announces Initiation Of A Multicenter Phase 2 Trial Of Poziotinib In Non-Small Cell Lung Cancer (NSCLC) Patients With Exon 20 Insertion Mutation In EGFR Or HER2

Spectrum Pharmaceuticals Announces Initiation Of A Multicenter Phase 2 Trial Of Poziotinib In Non-Small Cell Lung Cancer (NSCLC) Patients With Exon 20 Insertion Mutation In EGFR Or HER2

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today the initiation of a...

Spectrum Pharmaceuticals Announces Third Quarter 2017 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Third Quarter 2017 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a...

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

The Henderson, Nev.-based company said interim data from a Phase 2 study showed an objective response rate of 73%.

Spectrum Pharmaceuticals Highlights Poziotinib Data In Non-Small-Cell Lung Cancer (NSCLC) Presented At The 18th IASLC World Conference On Lung Cancer In Japan

Spectrum Pharmaceuticals Highlights Poziotinib Data In Non-Small-Cell Lung Cancer (NSCLC) Presented At The 18th IASLC World Conference On Lung Cancer In Japan

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced the oral presentation of...

Spectrum Pharmaceuticals Announces Agreements To Exchange $69.5 Million In Principal Amount Of Its 2.75% Convertible Senior Notes Due 2018 For Common Stock And Cash

Spectrum Pharmaceuticals Announces Agreements To Exchange $69.5 Million In Principal Amount Of Its 2.75% Convertible Senior Notes Due 2018 For Common Stock And Cash

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 2.

Spectrum Pharmaceuticals Provides Update On At-The-Market Facility

Spectrum Pharmaceuticals Provides Update On At-The-Market Facility

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced that between August 11,...

Spectrum Pharmaceuticals Highlights Poziotinib Data In Lung Cancer To Be Presented In An Oral Presentation At The 18th IASLC World Conference On Lung Cancer In Yokohama, Japan, October 15-18, 2017

Spectrum Pharmaceuticals Highlights Poziotinib Data In Lung Cancer To Be Presented In An Oral Presentation At The 18th IASLC World Conference On Lung Cancer In Yokohama, Japan, October 15-18, 2017

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced the release of an abstract...

First Week Of May 2018 Options Trading For Spectrum Pharmaceuticals (SPPI)

First Week Of May 2018 Options Trading For Spectrum Pharmaceuticals (SPPI)

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading this week, for the May 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Spectrum Pharmaceuticals To Present At Two Upcoming Investor Conferences In September

Spectrum Pharmaceuticals To Present At Two Upcoming Investor Conferences In September

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACY, BCOR, CVV, ENFC, ESSA, FCCY, FORD, GNBC, GRVY, GSM, LMNR, LMRK, OSTK, PMBC, SMMF, SPPI, WEB Downgrades: AEY, AMC, CAH, GEO, GNRT, HMNF, JOB, MTR, VIRC Initiations: GCP, YIN Read on to get TheStreet Quant Ratings' detailed report:

Spectrum Pharmaceuticals To Present Corporate Update At The 2017 Southern California Investor Conference In Newport Beach On Thursday, August 24th

Spectrum Pharmaceuticals To Present Corporate Update At The 2017 Southern California Investor Conference In Newport Beach On Thursday, August 24th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Spectrum Pharmaceuticals Announces Initiation Of The Registrational Phase 3 Trial Of Qapzola™ (apaziquone) In Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Spectrum Pharmaceuticals Announces Initiation Of The Registrational Phase 3 Trial Of Qapzola™ (apaziquone) In Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today the Company has...

Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today financial results...

Spectrum Pharmaceuticals Announces Completion Of Enrollment In The Phase 3 Pivotal Study (ADVANCE) Of ROLONTIS™ (eflapegrastim), A Novel Long-Acting GCSF

Spectrum Pharmaceuticals Announces Completion Of Enrollment In The Phase 3 Pivotal Study (ADVANCE) Of ROLONTIS™ (eflapegrastim), A Novel Long-Acting GCSF

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today the Company has...

Spectrum Pharmaceuticals Highlights Results Of A Combination Study Of FOLOTYN® (pralatrexate Injection) Plus Romidepsin Presented At The 14th International Conference On Malignant Lymphoma (14-ICML) Meeting

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced the presentation of data...

Spectrum Pharmaceuticals Highlights Three Abstracts Of Clinical Data At The 2017 American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago, Illinois, June 2-6, 2017

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced presentations of...

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2017 Global Healthcare Conference On June 6th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Spectrum Pharmaceuticals To Present Corporate Update At The Bank Of America Merrill Lynch 2017 Health Care Conference On May 17

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

TheStreet Quant Rating: C- (Hold)